Sort
51,593 grants matching “hepatitis”
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
$999,799Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2023 · HL
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
$999,799Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2024 · HL
Point-of-Care Rapid RNA test for HIV
$999,743Hyundae Cho · Crosslife Technologies, Inc. · R44 · FY2018 · AI
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
$999,652Ian James Amanna · Najit Technologies, Inc. · U44 · FY2021 · AI
Development of an H2O2-inactivated chikungunya virus vaccine
$999,652Ian James Amanna · Najit Technologies, Inc. · R44 · FY2017 · AI
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass
$999,580Jonathan A Winger · Omniox, Inc. · R44 · FY2023 · HD
Core D: Clinical Research Core
$999,419Ighovwerha Ofotokun · Emory University · P30 · FY2019 · AI
Rapid point-of-care molecular test for HCV VL
$999,310Jay Kenneth Fisher · Redbud Labs, Inc. · R44 · FY2024 · AI
NDA-Enabling Phase I Lofexidine Program
$999,244James Alvan Longstreth · Us Worldmeds, Llc · U01 · FY2011 · DA
Directed Transport Physics and Muli-Scale Therapy of Colon Cancer Liver Metatasis
$999,213Mauro Ferrari · Methodist Hospital Research Institute · U54 · FY2012 · CA
Mechanisms of Drug Disposition During Pregnancy
$998,989Jashvant D Unadkat · University Of Washington · P01 · FY2017 · DA
Novel therapy for Fragile X syndrome
$998,958Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2021 · MH
Development of a kit for the targeted depletion of abundant sequencesfromDNA/RNA libraries
$998,921Meredith Lauren Carpenter · Arc Bio, Llc · R44 · FY2019 · AI
Development of a kit for the targeted depletion of abundant sequencesfromDNA/RNA libraries
$998,921Meredith Lauren Carpenter · Arc Bio, Llc · R44 · FY2018 · AI
CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE
$998,793Robert S Sandler · Univ Of North Carolina Chapel Hill · P30 · FY2006 · DK
Building on Needle Exchange to Optimize HIV Prevention/Treatment
$998,636Gregory M Lucas · Johns Hopkins University · R01 · FY2020 · DA
Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
$998,596Gal Shafirstein · Pop Biotechnologies, Inc · R42 · FY2023 · CA
Supported employment to create a community culture of SARS-CoV-2 rapid testing among people who inject drugs: PeerConnect2Test
$997,902Camille C Cioffi · University Of Oregon · U01 · FY2023 · DA
Building on Needle Exchange to Optimize HIV Prevention/Treatment
$997,878Gregory M Lucas · Johns Hopkins University · R01 · FY2021 · DA
Mechanisms of Drug Disposition During Pregnancy
$997,675Jashvant D Unadkat · University Of Washington · P01 · FY2014 · DA
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
$997,662Ian James Amanna · Najit Technologies, Inc. · U44 · FY2022 · AI
Establishment/Maintenance of Biomedical Research Colony
$997,433Thomas J. Rowell · University Of Louisiana At Lafayette · U42 · FY2006 · RR
Adaptable tissue-specific endothelial cells for organ regeneration
$997,417Shahin Rafii · Weill Medical Coll Of Cornell Univ · R35 · FY2024 · HL
Center for Cellular Metabolism Research in Oklahoma
$997,408Lijun Xia · Oklahoma Medical Research Foundation · P20 · FY2024 · GM
Mechanisms of Therapy and Model Development in Viral Hepatitis and Liver Diseases
$997,377T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK